CYPH

Cypherpunk Technologies Inc. (CYPH) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) operates a dual strategy: a privacy technology business focused on accumulating Zcash (ZEC) as a digital asset treasury, and a biotechnology subsidiary, Leap Therapeutics, Inc., developing the cancer drug sirexatamab (DKN-01). The company is a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Q2 2026 net income was driven by a $46.0 million unrealized gain on the change in fair value of the embedded derivative associated with ZEC holdings. YTD 2026 reflects a $31.6 million unrealized loss on the same item.

Material Changes vs. Prior Period

• Profitability Shift: The company reported a net income of $39.4 million for Q2 2026, a reversal from the $16.6 million net loss in Q2 2025. This is primarily due to the volatility of ZEC prices resulting in a $46.0 million unrealized gain in Q2 2026, compared to no such gain in the prior year.
• Expense Reduction: Research and Development (R&D) expenses plummeted to $0.2 million in Q2 2026 from $10.5 million in Q2 2025. This decrease follows the completion of the DeFianCe clinical trial and a significant workforce reduction (approx. 75%) in mid-2025.
• General & Administrative (G&A) Increase: G&A expenses rose to $4.5 million in Q2 2026 from $1.8 million in Q2 2025, largely due to increased stock-based compensation from RSU grants and higher professional fees related to digital asset auditing.
• Liquidity: Cash and cash equivalents decreased from $14.0 million at year-end 2025 to $7.6 million at June 30, 2026, due to operating losses and $13.5 million in cash used to purchase ZEC tokens.

Guidance, Outlook, and Risks

• Biotech Outlook: The FDA granted Fast Track designation to sirexatamab for DKK1-high metastatic colorectal cancer. The company has reached alignment with the FDA on a Phase 3 trial design. A strategic process is underway to secure funding or a partnership to advance this program.
• Digital Asset Strategy: The company holds 323,394 ZEC tokens (approx. 1.92% of circulating supply). Management notes that ZEC price volatility significantly impacts financial statements. Subsequent events indicate ZEC prices ranged between $390 and $585 in July-August 2026.
• Liquidity & Going Concern: Management believes current cash ($7.6 million) and access to a $200 million ATM facility with Cantor Fitzgerald are sufficient to fund operations for the next 12 months. However, the company has an accumulated deficit of $500.3 million and expects to continue generating operating losses.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting that remained unremediated as of June 30, 2026. Consequently, disclosure controls and procedures were deemed ineffective.
• Risks: Key risks include the failure of the strategic process for the biotech arm, regulatory hurdles for sirexatamab, extreme volatility in ZEC prices, and the inability to raise additional capital.

Investor Verification Checklist

• Derivative Accounting: Verify the valuation methodology for the "embedded derivative" on ZEC holdings, as this single line item swings net income by tens of millions of dollars.
• Cash Burn Rate: Confirm the runway provided by the $7.6 million cash balance against the reduced but ongoing G&A and R&D costs.
• Material Weakness Remediation: Review the specific remediation plan for the internal control material weakness and its timeline for resolution.
• Strategic Process Status: Monitor updates on the strategic process for the Leap Therapeutics subsidiary to determine if a partnership or sale is imminent.
• ZEC Custody: Confirm the security and custody arrangements with Gemini Space Sciences LLC for the $129.4 million digital asset holding.